

# The supply of plasma-derived medicinal products in the future of Europe

**28/29**  
April 2022  
Rome, Italy

## AULA POCCHIARI

Istituto Superiore di Sanità  
**Viale Regina Elena, 299**

This event is organised by the Italian National Blood Centre, in collaboration with the International Federation of Blood Donor Organisations (IFBDO-FIODS), and it involves national and international key actors.

The main objectives of the scientific conference are to share the evolution of the national and international scenarios of plasma-derived medicinal products (PDMPs) demand and to discuss future perspectives and strategies to achieve a European PDMPs self-sufficiency.

# PROGRAMME / DAY 1

**08:30 Registration**

**09:30 Welcome address**

*Ministry of Health*

Clive Ondari, Coordinator, Policy, Access and Rational Use, World Health Organization  
Gian Franco Massaro, President, International Federation of Blood Donor Organisations  
Vincenzo De Angelis, Director, Italian National Blood Centre, Italian National Institute of Health

**10:00 Introduction**

Silvio Brusaferro, President of the Italian National Institute of Health

## **SESSION 1 / THE DEMAND FOR PLASMA-DERIVED MEDICINAL PRODUCTS**

Chairpersons: K. Magnussen, N. Magrini

**10:15 The demand for PDMPs:  
concepts, methodologies,  
measurements**  
G. Mazzaglia

**10:35 The global demand for PDMPs:  
current scenario and  
future trends**  
P. Robert

**Analysis of demand for PDMPs in:**

**10:55 Italy**  
F. Candura

**11:10 Australia**  
J. Pink

**11:25 Break**

**11:40 Canada**  
S. Grenier

**11:55 France**  
F. Rossi

**12:10 England**  
G. Gogarty

**12:25 Germany**  
M. Heiden

**12:40 Questions & Answers**

**13:00 Lunch break**

## **SESSION 2 / CLINICAL USE AND FUTURE TRENDS**

Chairpersons: P. M. Mannucci, L. De Marco

**14:00 Polyvalent immunoglobulins**  
I. Quinti

**14:25 Albumin**  
S. D. Ryder

**14:50 Factor VIII and other  
coagulation factors**  
O. B. Zülfikar

**15:15 Alpha-1-Proteinase Inhibitor**  
S. Scarlata

**15:40 C1-Esterase Inhibitors**  
M. Cancian

**16:05 Round table on  
Ethical reasons for  
patients and for donors**

**Chairpersons:**  
L. Montrasio, D. Di Giorgio

**Panelists:**  
Y. Maryuningsih  
K. Magnussen  
G. Briola  
E. Ferri Grazzi  
A. Gressani  
A. Segato  
C. Smit

**16:45 End of the day**

# PROGRAMME / DAY 2

## SESSION 3 / PLASMA SUPPLY AND PLASMA-DERIVED MEDICINAL PRODUCTS MANUFACTURING: EXPERIENCES FROM FRACTIONATION INDUSTRIES AND SOME EUROPEAN COUNTRIES

Chairpersons: A. Farrugia, R. Conocchia

**09:00 International Plasma and Fractionation Association**  
L. von Bonsdorff

**09:15 Plasma Protein Therapeutics Association**  
M. Van Baelen

**09:30 Italy**  
C. Sardella

**09:45 Austria**  
M. Jarnig

**10:00 Czech Republic**  
V. Řeháček

**10:15 France**  
J. B. Thibert

**10:30 Break**

**11:00 Denmark**  
M. B. Hansen

**11:15 Spain**  
M. A. Vesga Carasa

**11:30 The Netherlands**  
C. So-Osman

**11:45 Finland**  
L. von Bonsdorff

**12:00 Discussion**

**13:00 Lunch Break**

## Scientific Director:

Vincenzo De Angelis

## Scientific Secretariat:

Fabio Candura, Livia Cannata,  
Samantha Profili

## SESSION 4 / ARE THERE ANY PERSPECTIVES AND STRATEGIES FOR A COMMON POLICY FOR A EUROPEAN SELF-SUFFICIENCY ON PLASMA-DERIVED MEDICINAL PRODUCTS?

Chairpersons: V. De Angelis, J. Yu

**14:00 European Commission**  
S. Van Der Spiegel

**14:20 European Medicines Agency**  
R. Conocchia

**14:40 Council of Europe**  
R. Forde

**15:00 European Blood Alliance**  
P. Tiberghien

**15:20 SUPPLY project  
Strengthening voluntary  
non-remunerated plasma  
collection capacity in Europe**  
D. Thijssen-Timmer

**15:40 Discussion**

**16:00 Closing remarks**  
V. De Angelis

## Organizational Secretariat:

Lucia De Fulvio, Laura Di Marco,  
Maria Simona Massari, Francesca Molinaro

# Speakers and Chairpersons:

<b>Gianpietro Briola</b>	Interassociative Coordination of Italian Blood Volunteers
<b>Mauro Cianci</b>	Italian Network for the Hereditary and Acquired Angioedema, Department of Systems Medicine, University Hospital of Padua
<b>Fabio Candura</b>	Plasma and Plasma-Derived Medicinal Products Area, Italian National Blood Centre, National Institute of Health
<b>Roberto Conocchia</b>	European Medicine Agency
<b>Luigi De Marco</b>	Department of Translational Research, National Cancer Center, Aviano, Italy
<b>Domenico Di Giorgio</b>	Inspection & Certification Department, Pharmaceutical Crime Counteracting Office, Italian Medicines Agency
<b>Albert Farrugia</b>	University of Western Australia
<b>Enrico Ferri Grazzi</b>	Italian Federation of Haemophilia Patient Associations
<b>Richard Forde</b>	European Directorate for the Quality of Medicines & HealthCare
<b>Gerry Gogarty</b>	NHS Blood and Transplant, England
<b>Sylvain Grenier</b>	Plasma Protein and Related Products Formulary Program, Canadian Blood Services
<b>Andrea Gressani</b>	International Patient Organisation for Primary Immunodeficiencies
<b>Morten Bagge Hansen</b>	Rigshospitalet, University of Copenhagen, Denmark
<b>Margarethe Heiden</b>	Pharmacovigilance Department II, Paul-Ehrlich-Institute, Germany
<b>Markus Jarnig</b>	Blood Service Division, Blood Donation Center for Vienna, Lower Austria and Burgenland, Austria
<b>Karin Magnussen</b>	Dept. Blood Centre and Medical Biochemistry, Innlandet Hospital Trust, Norway. International Federation of Blood Donor Organisations
<b>Nicola Magrini</b>	Italian Medicines Agency
<b>P. Mannuccio Mannucci</b>	University of Milan, Italy
<b>Yuyun Maryuningsih</b>	Blood and other Products of Human Origin, Technical Standard and Specifications Unit, World Health Organization
<b>Giampiero Mazzaglia</b>	University of Milan – "Bicocca", Italy
<b>Lorenzo Montrasio</b>	Equity of access to innovative treatments, Human Rights Directorate, Council of Europe
<b>Joanne Pink</b>	Clinical Service and Research, Australian Red Cross
<b>Isabella Quinti</b>	Primary Immunodeficiencies Unit, Policlinico Umberto I, Sapienza University of Rome, Italy
<b>Vít Řeháček</b>	National Blood Transfusion Committee, Czech Republic
<b>Patrick Robert</b>	Marketing Research Bureau, U.S.A.
<b>Stephen D. Ryder</b>	NIHR Nottingham Clinical Research Facility, U.K.
<b>Françoise Rossi</b>	International Plasma and Fractionation Association
<b>Corrado Sardella</b>	Local Health Authority No.7 - Veneto Region, Italy
<b>Simone Scarlata</b>	Campus Bio-Medico University Hospital, Rome, Italy
<b>Alessandro Segato</b>	Italian Primary Immunodeficiency Association
<b>Cees Smit</b>	European Haemophilia Consortium
<b>Cynthia So-Osman</b>	Sanquin Bloodbank, and Erasmus – Medical Center, The Netherlands
<b>Jean Baptiste Thibert</b>	Biology-Therapies-Diagnostics, Etablissement Français du Sang, France
<b>Pierre Tiberghien</b>	European Blood Alliance
<b>Maaerten Van Baelen</b>	Plasma Protein Therapeutics Association
<b>Stefaan Van der Spiegel</b>	Sector-Health Innovation, DG Sant, European Commission
<b>Daphne Thijssen-Timmer</b>	Blood Bank, Sanquin, The Netherlands
<b>Miguel Angel Vesga Carasa</b>	Osakidetza Health Department, Spain
<b>Leni Von Bonsdorff</b>	International Plasma and Fractionation Association
<b>Junping Yu</b>	Blood & Transfusion Safety, World Health Organization
<b>Osman Bulent Zülfikar</b>	Haemophilia Society of Turkey, Istanbul University